Molecular properties
- Formula
- C16H21N3O2
- Molar mass
- 287.36 g·mol−1
- Exact mass
- 287.1634 Da
- 8
- PubChem CID
- 60857
Molecule record
(4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one
C16H21N3O2
287.36 g/mol
Loading structure
Functional groups
Alkane / alkyl carbon
Amide
Aromatic ring
Ester
Ether
Secondary amine
Tertiary amine
Physical properties
No source-backed physical properties are curated for this molecule yet.
Common names and synonyms
- (S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone
- (S)-4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-1,3-oxazolidin-2-one
- 139264-17-8
- 2-Oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-, (S)-
- 2FS66TH3YW
- 311-C-90
- 311C90
- 4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone
Show all 24 synonyms
- 4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one
- AscoTop
- CHEBI:10124
- Cvt-427
- DTXCID6025933
- DTXSID8045933
- N02CC03
- NSC-760383
- RefChem:57200
- Zolmiptriptan
- Zolmitriptan OD
- Zomig
- Zomig-ZMT
- Zomigoro
- zolmitriptan
- zolmitriptanum
Structure identifiers
- Canonical SMILES
- CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12
- Isomeric SMILES
- CN(C)CCC1=CNC2=C1C=C(C=C2)C[C@H]3COC(=O)N3
- InChI
- InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1
- InChIKey
- ULSDMUVEXKOYBU-ZDUSSCGKSA-N
- PubChem CID
- 60857
Spectroscopy
Tabs appear only for spectra stored with clear provenance.
No redistributable or simulated spectroscopy record is attached yet.
Simulated NMR
On-demand educational prediction for (4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one; not experimental data.
Simulated EI mass spectrum
On-demand educational fragmentation for (4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one; not experimental data.
Sources
Molecule identity
Retrieved 8/20/2026. Reuse status is summarized by the badge; open the source for full details.